Linker– tag –
-
Daiichi Sankyo’s Early ADC Pipeline Lags Rivals as Cash Flow Nears Peak, Incurs $850M Charges for Underutilized CMO Capacity
BioSpace USA Overview Jefferies analysts suggest Daiichi Sankyo's early-stage antibody-drug conjugate (ADC) pipeline is not keeping pace with rivals, despite the success of Enhertu and Datroway. Enhertu and Datroway are nearing peak reve... -
Lonza and Engitix Ink ADC License Deal for ECM-Targeted Cancer, Fibrosis Therapies
GEN (Genetic Engineering & Biotechnology News) Switzerland Overview Lonza and Engitix Ltd. have signed a licensing agreement for an Antibody-Drug Conjugate (ADC) technology platform, targeting cancer and fibrosis therapies focused on the... -
Akari Therapeutics and Whitehawk Therapeutics Partner on Trop2-Targeting ADC AKTX-101, Leveraging Novel PH1 Payload for Immune Activation
Markets Insider USA Overview Akari Therapeutics has entered a strategic research collaboration with Whitehawk Therapeutics to advance its next-generation Antibody-Drug Conjugate (ADC) lead candidate, AKTX-101. AKTX-101 targets the Trop2 ... -
Antibody-Drug Conjugates Evolve from ‘Magic Bullet’ to Standard of Care in Solid Tumors, T-DXd and Combination Therapies Set New Benchmarks
Binaytara USA Overview Antibody-Drug Conjugates (ADCs) have significantly evolved in solid tumor treatment, transitioning from a 'magic bullet' concept to a 'standard of care.' Globally, over 12 ADCs are approved, with more than 300 in c... -
Antibody-Drug Conjugates Evolve into Smart Chemotherapy, Datroway Gains FDA Approval for Metastatic Triple-Negative Breast Cancer
Karchem Consulting USA Overview Antibody-Drug Conjugates (ADCs) are evolving into next-generation 'smart chemotherapies' by integrating precise targeting with innovative linker-payload technologies. Novel drug classes like nucleic acid a... -
Antibody-Drug Conjugates (ADCs) Evolve to Standard of Care in Solid Tumor Treatment: 12 Approved, 300 in Development, Focusing on Patient Wellness and Dual-Payload Strategies
Cancer News - Binaytara USA Overview Antibody-drug conjugates (ADCs) have dramatically evolved from 'magic bullets' to a standard of care in cancer treatment, with 12 ADCs approved globally and over 300 in clinical development. This evol... -
Lonza Offers Integrated ADC Clinical and Commercial Manufacturing Services, Covering Antibody to Sterile Fill-Finish
Lonza Switzerland Overview Lonza offers integrated development and manufacturing services for Antibody-Drug Conjugates (ADCs), encompassing antibodies, payloads, bioconjugation, and sterile fill and finish. The company operates GMP produ... -
Pfizer Discontinues Seagen-Developed Solid Tumor ADC Program SGN-MesoC2, Highlighting Persistent ADC Development Challenges
BioSpace USA Overview Pfizer has discontinued another Seagen-developed antibody-drug conjugate (ADC) program for solid tumors, SGN-MesoC2, just weeks after another Seagen-acquired ADC failed a Phase 3 lung cancer study. This cessation un... -
ASCO Podcast: Optimizing Frontline ADCs as They Shift to Earlier Cancer Treatment Stages
ASCO Publications USA Overview An ASCO Publications podcast discusses the rapid integration of antibody-drug conjugates (ADCs) into frontline advanced and curative-intent perioperative settings for cancer treatment. Experts emphasize tha... -
Optimal Payload Linker Selection is Critical for ADC Development, Balancing Efficacy, Safety, and Stability
Chemexpress China Overview This guide highlights the critical role of selecting the right payload linker for successful antibody-drug conjugate (ADC) programs. Linker design dictates the balance between efficacy, safety, stability, and m...
